Century Therapeutics (IPSC) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Protalix BioTherapeutics (DE) (PLX) over the past year, gaining 129.0% versus a gain of 8.4%. Over five years, PLX leads with a +120.3% price change compared with -93.4% for IPSC. Century Therapeutics is the larger company by market cap ($231.8 million vs $218.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | PLX |
|---|---|---|
| Share price | $1.28 | $2.71 |
| Market cap | $231.78M | $218.35M |
| 1-day change | -3.03% | -0.73% |
| YTD return | +28.64% | +50.56% |
| 1-year return | +128.98% | +8.40% |
| 5-year return | -93.37% | +120.33% |
| P/E ratio (TTM) | — | 11.78 |
| Forward P/E | — | 4.37 |
| EPS (TTM) | $-0.93 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $3.19 |
| 52-week low | $0.435 | $1.60 |
| Distance from 52-week high | -57.89% | -15.05% |
| Average volume | 658.60K | 729.36K |
| Shares outstanding | 181.08M | 80.57M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed PLX by 120.6 percentage points over the past year.
IPSC vs PLX FAQ
Which is bigger, Century Therapeutics or Protalix BioTherapeutics (DE)?
Century Therapeutics (IPSC) is larger, with a market capitalization of $231.78M compared with $218.35M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, IPSC or PLX?
IPSC returned +128.98% over the past 12 months, compared with +8.40% for PLX (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.